<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="214950">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00287417</url>
  </required_header>
  <id_info>
    <org_study_id>3032</org_study_id>
    <nct_id>NCT00287417</nct_id>
  </id_info>
  <brief_title>Early Ultrasound and Maternal Biochemical Markers to Evaluate the Risk of Down Syndrome During the First Trimester</brief_title>
  <official_title>Nuchal Translucency Study - PAPP-A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the risk of Down syndrome during the first trimester of
      the pregnancy. The risk assessment is evaluated using early ultrasound and maternal
      biochemical markers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">20000</enrollment>
  <condition>Down Syndrome</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>echography</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinics, public hospitals
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female &gt; 18 years old

          -  Pregnant

        Exclusion Criteria:

          -  Maternal age &lt; 18 years old, twin pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Israel Nisand, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Département de Gynécologie-Obstétrique, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <state>Alsace</state>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Gynécologie-Obstétrique, SIHCUS, CMCO</name>
      <address>
        <city>Strasbourg</city>
        <state>Alsace</state>
        <zip>67303</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Belfort</city>
        <zip>90000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Mère et Enfant LE PARC, Service de Gynécologie Obstétrique</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Périnatalité, Hôpital Civil</name>
      <address>
        <city>Guebwiller</city>
        <zip>68500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier du Hasenrain</name>
      <address>
        <city>Mulhouse</city>
        <zip>68051</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique ADASSA</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <lastchanged_date>May 13, 2011</lastchanged_date>
  <firstreceived_date>September 13, 2005</firstreceived_date>
  <responsible_party>
    <name_title>Emmanuel LAVOUE, Directeur Adjoint de la DRCI</name_title>
    <organization>University Hospital, Strasbourg, France</organization>
  </responsible_party>
  <keyword>Nucal translucency</keyword>
  <keyword>Down syndrome</keyword>
  <keyword>MSS</keyword>
  <keyword>Risk assessment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Down Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
